Oncology

Latest News

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo